HUE030856T2 - NEIL3 peptideket és az azokat tartalmazó vakcinák - Google Patents

NEIL3 peptideket és az azokat tartalmazó vakcinák Download PDF

Info

Publication number
HUE030856T2
HUE030856T2 HUE10753267A HUE10753267A HUE030856T2 HU E030856 T2 HUE030856 T2 HU E030856T2 HU E10753267 A HUE10753267 A HU E10753267A HU E10753267 A HUE10753267 A HU E10753267A HU E030856 T2 HUE030856 T2 HU E030856T2
Authority
HU
Hungary
Prior art keywords
neil3
peptides
peptide
cancer
seq
Prior art date
Application number
HUE10753267A
Other languages
English (en)
Inventor
Takuya Tsunoda
Ryuji Ohsawa
Sachiko Yoshimura
Tomohisa Watanabe
Yusuke Nakamura
Yoichi Furukawa
Original Assignee
Oncotherapy Science Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncotherapy Science Inc filed Critical Oncotherapy Science Inc
Publication of HUE030856T2 publication Critical patent/HUE030856T2/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y402/00—Carbon-oxygen lyases (4.2)
    • C12Y402/99—Other carbon-oxygen lyases (4.2.99)
    • C12Y402/99018—DNA-(apurinic or apyrimidinic site)lyase (4.2.99.18)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)

Claims (4)

  1. I,JI 8sm8<iS8Vä'tallte4:! :¾¾ slá^slilp és (si) llkt Ä:Qio^i:«sfipg*ii|&amp;#|Etette ; :) s? alábbi u·.} vagy (b) szerit«» Izolált pepiid: (gj izolálj:- ppíi, tetely a SisQ 10 ICk Μ M 41 ÄI alkotott csöfxathöi kiválasztott ammo«tv-s»?kY»aciái tartalmaz; |í>) .izolált' pepid, atsdy a SEQ ÎÏ3 t&amp;&amp; 24, 2% 35; ;4î «s 4¾ sla! ^Ikffotí vsöpstTbél kiválása:» smifeôsav-sxékvësÂ: ktilAtav, aminée» I vagy 3i: ateosav «äg|®Ä^ly·^ ^gbiélva vagy s4dSeiösá!eva: vaa, ak4::8 |)spîi^ CTI. io4t&amp;Aatlbág%^si Ú3í a/ »Md y:î ^.ïgs u>t vmsïi »» p-egdd: íc) »iák pepid, amdy a »Q ΙΠ ΝΌ; 5, i, 4f δ, Π, i>. Tg 31 és 22 Thai alkoké cyípottfeós kn».v-rsu Äs"i3TX'»,k -ÎiCVvUk'va sandáik 3-% (d> izolál! pepiid, aííiíiy a SkQ !D NO' 5, X 4, 6, Ti, ;!TS ;|TS 31 és 22 állal alkotóit esupodk# ksválasztmt afnim^av-siskvotKiát tartalma*, amelyben I vagy 2 attottosav u»bs*muálvat: neSölátvá: vagy uddidonáicva van, ahol &amp; pepiid CTÍ- tndukálaato^i: t. A* h igâ«>-pont §«» izolál» |kífíkk afel « agy tök« »vitel teitesággtl rendelteik- Ç%) g SCO 10 Nf) 24. 21, ¾ 41 vagy 45 xaerötii ;&amp;mmo$.av·saekveocia N-krtnmáikáiél «»átaxhk amíö;x.ev 4‘'’itlvk|tld41 va vád ti Hílilitlaottt., ti,’-vie, töet ,οΜ:, v,, triptotávi é,e*,: ,ίΐοίοο csíawdx>; kiválasztott áayippmí; és §3| a IFÇ 114 Ä? » 44 IS, 44 ysá? 41 -s^erMi omhossv-stevatte C-terminálls ::sminosavs Mvtnnímrn *m·. a fe«Ä: *¥Ä és ûûimim IM. alkotod WÄM k !VsIe,sskö: smistöSávvak %Aá L igénypont «Mt P»M $&amp; 3 ^ egy vagy mix« követtel rendelteik: (a) a St-Q ii> NO: 5, 5. 4, 1,1¾ l:S, r?> 31 vagy 32 szerMt •^^»lermmálbS^ tetetik atninoatv stetetete w * «» ^ Âï kteitilM 8Ö3Í8ÖSaVV8ljéS (ét sí NbQ ID NO;: .5, 3» 4« 6, 5 I, .15, .17, 21 vagy 22 szerintii aminosávvkaekvenda €~ífi?mifiálk armoos&amp;vs szsbsÄfc vao s:A# leueæ âltgl áttoló?* esó|xinból kiváláson amisősavval.
  2. 4, Λχ· I ' ägeosposaok bbmrb As wv&amp;t srfeH pcpttd =rovh «of^Mfesagt vVkapep*,d i* i: vs»gy 4 igéssfissid ^fell-.feláll pepiid, ;dsi a pptM &amp; SEQ IO NO: S, 3, 4. b, U, 15, i?.2i. 22, 24, '< } í'\l \£ l *k !ΛΧ^\" >"> S^i'.^xSiXÍ άΟι! <V, V N s\'v»x I'D ts b |/<4<Ή popnskKnal »««rix ** 1-3. tgs *>χ noo.ok b*«· nők jke széna» peptfetkodof. ?. Készítmény, »mely egy vagy több 1-5. igénypontok bármelyike szer««) pitidet vagy egy vagy otÄtlr igénypont s^rimi^«uikk<dlé»-Í8Jl#teíi H, Gymyyáv/mi készítmény, amely egy vagy több N5. igêtsyposiok bármelyike szedőd pepiidet vagy egy vagy több * íggotport SMsmi gobaokfeoska ut*fe»oz
    4. Λ a: i-S. }gé«yp«»tok bármelyike s«rism pepiid, a Is. s*«rf«H .pöim»yéöt«Í vagy a 7. vagy 8Ë igénypont szériát) késziffeö?, gyógyszerkén; tfttôtô alkalmazásra. Nk Az ! N igény pmsiok bànnvbske a se », a\lsd Ui igét > pora stenot pofekk-otd ν«νΛ <, ~ sags 8 Igénypont szerinti készítmény, rak kezdésében vagy megelőzésében os/vagy atmak roőté? oláni. kisáj«lásán»k megelőzésébe« törtét}« a&amp;dmsfesra. INA 10. igénypert« ^.enoti, ;ák keaélfeéfaen. vagy soogpiífesábés és/vagy annak rabiét «tára ktfelàsÉÂ megelőzésbe« történő tfk&amp;lwMMm szolgáló ptptid, pohauktexHtd vagy készítmény, olyan daaysui, törteső híradásra, smeiyoek « Hl.A anbgesne HLA~A24 vagy HLA--A2. 12, ín vstro eljárás CTL inthsiiáihaióságö ant^fepmeníáló sejt (ΛΡΟ «Hkíkáláséra, assely a kővetkezők által alkotod csoportból kiválasztott lépést íoglsl-magában; (c- A 1*0 enoiktztdevea/ i-á sgenj pontok batrreiytke ezet mb pepnddei so vitro, és lé; ne 1*3. igénypontok bármelyike szent«; pepiidet kódold poiraiskkxásd bejuttatás« ΛΚ.'-be át váró. 1:3, Iá vkm o|Ítás CIi, md«kátásara:i a következők által alkottat csoportból kiYà1#l^tté|^::Â^àb8ôÂ^I4 eljárással: (<)> t DS píVítiV 1 vegek zg> Arazmraz; v»c APí 4 két, ameh a tebzekm ül A antigen os «z |ra sgeoyposuok wbrnek »< szí, · om |\ρΡ,Ι komplexet pse/eotab&amp;, tbs CDb poíitix 1 «epek eg\ etH.eavAmmse exoszómakkai, amely a ifb.rtmm tb \ antígv-s ^ \ < ««es'vpvsvosv 't,«s J, se **, o j\pt«d v*ts'pD\á' pt, f «té o- •%|· 'Φ É*5, :i||ttypÍ8ÍÉÍk fesselyÉe .szeriSir;:||^p^h«z.lkötÄ '11. ts^ji receptor pßiE) alegység: ttbllséélddeiiiÖdőlá'sdliMkkaÉkM.feaksasÉ. s:fe::beí«iatáas Τ' vcítbo. U Ifoiu W i‘O Ms ! N.sSy! - ' * * ΛΙ» 's M* ' s'ti < 1' Λ8ΪΚ no «l'VA piSiXînsâljiî. 1$. Λ h. IWaÄa» lé» kóláit c í'L, aífíStpÉ j-^Nl:WPÄ ¥Np?tó.
  3. 17. Λ ifi }gé»v{x:-í« s*x«tmtí C 1 U^mely a i 3 igénypont sïænniî eljárása! va« ϋώ$$|ν*' mmmám^ W$ä$&amp;1 $!:»smdviko sztrimt peptidet &amp;. :iilÄ·f:i|i^|:tatíí||asaé komplexes prcAouál. Î9, Α.·>: I -·>. IgèoypoïOok bánadsike .«aiimí ix-ptld síkod dkossnyag vagy tVagnäensev 2P X >'U li.u ^'nvps « sa s as r> o tk μ\1ο o sí >kk\ h is. v.. «u > i* « ist« ísiw '11. Oíí-ítlassp, .«sidy 2Ö. sgd;ypont s/ennti expîx«;;:ïi6i voktost&amp;l va« irasisxtúíxsndva vagy tniiik&amp;ÄtsiYä.
  4. 22. Dlagmn«tik&amp;s ké&amp;tteu aw«l> ;*?. 1-5. igénypontok bàrsneîyîk* .-szííésÍííÍéI::--':;i^Éi^sont ssatMt pollfníklsotkloi vagy a íf? igénypont szensdi ellenanyagot tarkslmsía.
HUE10753267A 2009-03-18 2010-03-15 NEIL3 peptideket és az azokat tartalmazó vakcinák HUE030856T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US21051209P 2009-03-18 2009-03-18

Publications (1)

Publication Number Publication Date
HUE030856T2 true HUE030856T2 (hu) 2017-06-28

Family

ID=42739437

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE10753267A HUE030856T2 (hu) 2009-03-18 2010-03-15 NEIL3 peptideket és az azokat tartalmazó vakcinák

Country Status (20)

Country Link
US (4) US9045557B2 (hu)
EP (1) EP2408913B1 (hu)
JP (3) JP5799394B2 (hu)
KR (1) KR101744514B1 (hu)
CN (2) CN102356155B (hu)
BR (1) BRPI1009301A2 (hu)
CA (1) CA2755342C (hu)
DK (1) DK2408913T3 (hu)
ES (1) ES2617434T3 (hu)
HU (1) HUE030856T2 (hu)
IL (2) IL214130A (hu)
MX (1) MX2011007963A (hu)
NZ (1) NZ594198A (hu)
PL (1) PL2408913T3 (hu)
PT (1) PT2408913T (hu)
RU (2) RU2600888C2 (hu)
SG (2) SG174120A1 (hu)
TW (2) TWI568444B (hu)
WO (1) WO2010106770A1 (hu)
ZA (1) ZA201107356B (hu)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI469791B (zh) 2009-02-18 2015-01-21 Oncotherapy Science Inc Ｆｏｘｍ１胜肽以及含此胜肽之疫苗
EP2545171B1 (en) 2010-03-11 2017-12-20 OncoTherapy Science, Inc. Hjurp peptides and vaccines including the same
SG10201509823WA (en) 2010-12-02 2015-12-30 Oncotherapy Science Inc TOMM34 Peptides And Vaccines Including The Same
JP6159996B2 (ja) 2012-03-09 2017-07-12 株式会社富士薬品 ペプチドを含む医薬組成物
JP6078844B2 (ja) * 2012-09-26 2017-02-15 公立大学法人大阪市立大学 癌免疫療法のためのペプチド及びその利用
US11338026B2 (en) 2014-09-10 2022-05-24 The University Of Connecticut Identification of immunologically protective neo-epitopes for the treatment of cancers
WO2016040110A1 (en) * 2014-09-10 2016-03-17 The University Of Connecticut Identification of immunologically protective neo-epitopes for the treatment of cancers
JP6426486B2 (ja) * 2015-01-29 2018-11-21 京セラ株式会社 太陽電池素子の製造方法
US11920202B2 (en) 2020-04-09 2024-03-05 University Of Connecticut Unbiased identification of tumor rejection mediating neoepitopes

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
EP0239102A3 (en) 1986-03-28 1989-07-12 Tsuji, Kimiyoshi Process for the formation of human-human hybridoma
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
DE69133476T2 (de) 1990-08-29 2006-01-05 GenPharm International, Inc., Palo Alto Transgene Mäuse fähig zur Produktion heterologer Antikörper
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US6222012B1 (en) * 1992-08-31 2001-04-24 Ludwig Institute For Cancer Research Isolated nonapeptides presented by HLA molecules, and uses thereof
US5679647A (en) 1993-08-26 1997-10-21 The Regents Of The University Of California Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides
US5804566A (en) 1993-08-26 1998-09-08 The Regents Of The University Of California Methods and devices for immunizing a host through administration of naked polynucleotides with encode allergenic peptides
US5739118A (en) 1994-04-01 1998-04-14 Apollon, Inc. Compositions and methods for delivery of genetic material
US5736524A (en) 1994-11-14 1998-04-07 Merck & Co.,. Inc. Polynucleotide tuberculosis vaccine
US5922687A (en) 1995-05-04 1999-07-13 Board Of Trustees Of The Leland Stanford Junior University Intracellular delivery of nucleic acids using pressure
DE69635895D1 (de) 1995-08-03 2006-05-04 Rijksuniversiteit Te Leiden Le Antigen presentierende bläschen, die von zellen ableiten
US5853719A (en) 1996-04-30 1998-12-29 Duke University Methods for treating cancers and pathogen infections using antigen-presenting cells loaded with RNA
US6294378B1 (en) 1996-07-26 2001-09-25 Sloan-Kettering Institute For Cancer Research Method and reagents for genetic immunization
FR2766205B1 (fr) 1997-07-16 2002-08-30 Inst Nat Sante Rech Med Nouveau procede de sensibilisation de cellules presentatrices d'antigene et nouveaux moyens pour la mise en oeuvre du procede
EP1090924B8 (en) 1998-06-25 2007-11-21 Green Peptide Co., Ltd. Tumor antigen peptides originating in cyclophilin b
US6914128B1 (en) * 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
AU7721500A (en) * 1999-09-29 2001-04-30 Human Genome Sciences, Inc. Colon and colon cancer associated polynucleotides and polypeptides
US6436703B1 (en) * 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides
AU2001296235A1 (en) * 2000-10-12 2002-04-22 Hyseq, Inc. Novel nucleic acids and polypeptides
CA2440773A1 (en) 2001-03-14 2002-09-19 Dakocytomation Denmark A/S Novel mhc molecule constructs, and methods of employing these constructs for diagnosis and therapy, and uses of mhc molecules
US20040142325A1 (en) * 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
CA2399569A1 (en) 2001-09-25 2003-03-25 Yusuke Nakamura Diagnostic markers and drug targets for treatment of cancer
WO2003104275A2 (en) 2002-06-06 2003-12-18 Oncotherapy Science, Inc. Genes and polypeptides relating to human colon cancers
GB2392158B (en) 2002-08-21 2005-02-16 Proimmune Ltd Chimeric MHC protein and oligomer thereof
ATE531729T1 (de) * 2002-09-12 2011-11-15 Oncotherapy Science Inc Kdr-peptide und diese enthaltende impfstoffe
US20050048646A1 (en) * 2003-08-25 2005-03-03 Medinet Co., Ltd. Method for inducing cytotoxic T lymphocyte
JP4628208B2 (ja) * 2004-08-10 2011-02-09 オンコセラピー・サイエンス株式会社 Ｃｘａｄｒｌ１またはｇｃｕｄ１タンパク質を発現する胃癌または結腸直腸癌の治療のためのペプチドワクチン
US7915036B2 (en) 2004-09-13 2011-03-29 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Compositions comprising T cell receptors and methods of use thereof
US8003770B2 (en) 2005-09-13 2011-08-23 Mie University T-cell receptor and nucleic acid encoding the receptor
EP1938104A2 (en) * 2005-10-17 2008-07-02 Institute for Systems Biology Tissue-and serum-derived glycoproteins and methods of their use
DK1987178T3 (en) * 2006-02-20 2015-04-20 Phylogica Ltd Process for the construction and screening of peptide structure libraries
WO2008156827A2 (en) 2007-06-20 2008-12-24 Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Molecular grading methods for ductal carcinoma in situ

Also Published As

Publication number Publication date
US20160340398A1 (en) 2016-11-24
NZ594198A (en) 2013-11-29
CN102356155A (zh) 2012-02-15
PT2408913T (pt) 2017-03-07
TW201600107A (zh) 2016-01-01
KR101744514B1 (ko) 2017-06-08
SG174120A1 (en) 2011-10-28
US20150290307A1 (en) 2015-10-15
PL2408913T3 (pl) 2017-07-31
CN102356155B (zh) 2016-02-24
JP5799394B2 (ja) 2015-10-28
CN105601725B (zh) 2019-08-09
BRPI1009301A2 (pt) 2016-03-08
WO2010106770A1 (en) 2010-09-23
IL214130A (en) 2017-09-28
CA2755342C (en) 2017-10-03
TWI568444B (zh) 2017-02-01
RU2016138428A3 (hu) 2020-03-27
CN105601725A (zh) 2016-05-25
TWI608844B (zh) 2017-12-21
US20180222954A1 (en) 2018-08-09
JP2017132786A (ja) 2017-08-03
US9045557B2 (en) 2015-06-02
US9446106B2 (en) 2016-09-20
TW201043240A (en) 2010-12-16
RU2016138428A (ru) 2018-12-12
EP2408913A1 (en) 2012-01-25
SG2014013148A (en) 2014-07-30
JP2012520659A (ja) 2012-09-10
RU2733985C2 (ru) 2020-10-09
US10597431B2 (en) 2020-03-24
CA2755342A1 (en) 2010-09-23
EP2408913B1 (en) 2016-12-14
US20120093845A1 (en) 2012-04-19
KR20110139270A (ko) 2011-12-28
US9975935B2 (en) 2018-05-22
AU2010225997A1 (en) 2011-08-11
MX2011007963A (es) 2011-08-17
ES2617434T3 (es) 2017-06-19
IL229926A (en) 2016-11-30
IL214130A0 (en) 2011-08-31
DK2408913T3 (en) 2017-03-06
EP2408913A4 (en) 2012-11-14
JP2015227334A (ja) 2015-12-17
RU2600888C2 (ru) 2016-10-27
RU2011142036A (ru) 2013-04-27
ZA201107356B (en) 2012-07-25
IL229926A0 (en) 2014-01-30

Similar Documents

Publication Publication Date Title
US10597431B2 (en) NEIL3 peptides and vaccines including the same
US20170198010A1 (en) Tomm34 peptides and vaccines including the same
CA2761393A1 (en) Ttk peptides and vaccines including the same
AU2011225577B2 (en) HJURP peptides and vaccines including the same
WO2010113495A1 (en) C6orf167 peptides and vaccines containing the same
CA2782977A1 (en) Tmem22 peptides and vaccines including the same
CA2815100A1 (en) C18orf54 peptides and vaccines including the same
CA2815102A1 (en) Wdhd1 peptides and vaccines including the same
CA2795318A1 (en) Ect2 peptides and vaccines including the same
AU2010225997B2 (en) NEIL3 peptides and vaccines including the same
CA2782484A1 (en) Mybl2 peptides and vaccines containing the same
WO2011125139A1 (en) Cluap1 peptides and vaccines including the same